Results 271 to 280 of about 16,557,675 (399)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Exploring the interplay of electron density distribution and electrostatic potential in the interaction of nilutamide and flutamide with androgen receptors using quantum crystallography. [PDF]

RSC Adv
Balasubramanian H, Poomani K, Kandasamy S, Hathwar VR, Gonnade RG.   +4 more
europepmc   +1 more source

A Landscape of Pharmacogenomic Interactions in Cancer

Cell, 2016
F. Iorio, T. Knijnenburg, D. Vis, G. Bignell, Michael P. Menden, Michael Schubert, N. Aben, E. Gonçalves, S. Barthorpe, H. Lightfoot, T. Cokelaer, Patricia Greninger, E. van Dyk, Han Chang, Heshani de Silva, H. Heyn, Xianming Deng, Regina K. Egan, Qingsong Liu, T. Mironenko, Xeni Mitropoulos, L. Richardson, Jinhua Wang, Tinghu Zhang, S. Moran, Sergi Sayols, M. Soleimani, D. Tamborero, N. López-Bigas, P. Ross-Macdonald, M. Esteller, N. Gray, D. Haber, M. Stratton, C. Benes, L. Wessels, J. Saez-Rodriguez, U. McDermott, M. Garnett   +38 more
semanticscholar   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Protein-Protein Interactions Modulate a Key Branch Point in Monoterpene Indole Alkaloid Biosynthesis. [PDF]

ACS Chem Biol
Carr SC, McDonald A, Langley C, Grabe V, Gase K, O'Connor SE.   +5 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

A kinetic model for SCR coated particulate filters—Effect of ammonia-soot interactions

, 2018
Lidija V. Trandafilović, Oana Mihai, Jungwon Woo, Kirsten Leistner, Marie Stenfeldt, Louise Olsson   +5 more
openalex   +2 more sources

Genome-Wide Mapping of in Vivo Protein-DNA Interactions

Science, 2007
David S. Johnson, A. Mortazavi, R. Myers, B. Wold   +3 more
semanticscholar   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source